Table 5. COPD exacerbation annual rate in recent studies of ICS/LABA combinations.
| Study reference | Drugs and total daily dose (μg) | Study duration |
Annual rate of moderate/severe exacerbations
|
||
|---|---|---|---|---|---|
| ICS/LABA | LABA | Reduction ICS/LABA versus LABA (%) | |||
| Calverley et al. 3 | BUD/FF 800/24 versus FF 24 | 12 months | 1.38 | 1.85 | 25.5a |
| Calverley et al. 12 | FP/S 1000/100 versus S 100 | 3 years | 0.85 | 0.97 | 12a |
| Szafranski et al. 5 | BUD/FF 800/24 versus FF 24 | 12 months | 1.42 | 1.84 | 23a |
| Kardos et al. 45 | FP/S 1000/100 versus S 100 | 44 weeks | 0.92 | 1.4 | 35a |
| Ferguson et al. 4 | FP/S 500/100 versus S 100 | 12 months | 1.06 | 1.53 | 30.5a |
| Rennard et al. 7 | BUD/FF 400/12 versus FF 12 | 12 months | n/a | n/a | 25a |
| Rennard et al. 7 | BUD/FF 200/12 versus FF 12 | 12 months | n/a | n/a | 29a |
| Anzueto et al. 46 | FP/S 500/100 versus S 100 | 52 weeks | 1.10 | 1.59 | 30.4a |
| Sharafkhaneh et al. 44 | BUD/FF 400/12 versus FF 12 | 12 months | 0.70 | 1.07 | 34.6a |
| Sharafkhaneh et al. 44 | BUD/FF 200/12 versus FF 12 | 12 months | 0.79 | 1.07 | 25.9a |
| Dransfield et al. 6 | FF/Vil 100/25 versus Vil 25 | 52 weeks | 0.81 | 1.11 | 30b |
| Wedzicha et al. 28 | BDP/FF 400/24 versus FF 24 | 48 weeks | 0.80 | 1.12 | 28.1a |
Studies >6 months were included.
NCT00476099 excluded from this summary, because of a low exacerbation rate.20
Abbreviations: BDP/FF, beclometasone dipropionate/formoterol fumarate; BUD/FF, budesonide/formoterol fumarate; FP/S, fluticasone propionate/salmeterol; FF/Vil, fluticasone furoate/vilanterol.
a
P value ICS/LABA versus LABA alone <0.05.
b
P value not available.